Company & team
A focused team behind the research
The leadership and advisors below are those presented on the current company homepage (updated September 2026).
Leadership
Dr Mike Davies
MD, FRCS · CEO & Founder
The company profile describes an Edinburgh University background, surgical training and more than 25 years of drug-development experience. The company also states that he has personally invested over US$650,000 (an attributed website statement, not independently verified and not total company financing).
Anuj Madhok
PhD · CFO/CBO
His profile describes experience in strategy, business development and finance in biopharma, including a career metric of more than US$2 billion in value creation with a US$700 million exit — attributed to his career, not to Carocell Bio.
Scientific and clinical advisors
Professor Anne Dickinson
PhD · Scientific and Clinical Advisor
Listed as Emerita Professor at Newcastle University and Director of the Newcastle Cellular Therapies Facility.
Professor Yvonne Perrie
PhD · Scientific and Clinical Advisor
Listed with drug-delivery expertise at the Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde.
Other pages of the official site (such as “Who are we” and the 2024 annual update) list different or earlier roles. They are not merged here pending confirmation by the company.
Company details
- Legal name
- CAROCELL BIO LIMITED
- Company number
- 10469714
- Incorporated
- 8 November 2016
- Status
- Active
- Registered office
- London BioScience Innovation Centre (LBIC), 2 Royal College Street, London NW1 0NH
- US entity
- Carocell Bio, Inc — Charleston, SC (as published in the official site footer)
History
2016
CAROCELL BIO LIMITED incorporated in England (Companies House). An older investor deck refers to a 2017 founding of operations.
2019
Bridge Biotec announces its new name: Carocell Bio.
2021–22
Company announcements report Innovate UK grant support and Deepbridge Capital investments for preclinical work.
2022
Ethics permission announced for ex vivo research on human tissue.
2023
Company reports preclinical data from human skin biopsies.
2024
Boston Bootcamp selection and an annual update on dermatitis biopsies and formulation work.